| [1] |
Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors [J]. Nature, 2013, 500(7463): 486-489.
|
| [2] |
Canto MI, Setrakian S, Willis J, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett′s esophagus [J]. Gastrointest Endosc, 2000, 51(5): 560-568.
|
| [3] |
Dvo？ák V, Pilka R. Role of prebioptic and bioptic methodsin the screening and diagnosis of cervical cancer[J]. Ceska Gynekol, 2014, 79(2): 88-97.
|
| [4] |
Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening[J]. Vaccine, 2012, 30(Suppl 5): F107-F116.
|
| [5] |
Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents[J]. Adv Drug Deliv Rev, 2004, 56(8): 1143-1160.
|
| [6] |
Konda SD, Aref M, Brechbiel M, et al. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress[J]. Invest Radiol, 2000, 35(1): 50-57.
|
| [7] |
Meier R, Henning TD, Boddington S, et al. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133[J]. Radiology, 2010, 255(2): 527-535.
|
| [8] |
Bhunia SK, Maity AR, Nandi S, et al. Imaging cancer cells expressing the folate receptor with carbon dots produced from folic acid[J]. Chembiochem, 2016, 17(7): 614-619.
|
| [9] |
Jia X, Li J, Wang E. One-pot green synthesis of optically pH-sensitive carbon dots with upconversion luminescence[J]. Nanoscale, 2012, 4(18): 5572-5575.
|
| [10] |
Wang L, Zhu SJ, Wang HY, et al. Common origin of green luminescence in carbon nanodots and graphene quantum dots[J]. ACS Nano, 2014, 8(3): 2541-2547.
|
| [11] |
Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander？[J]. Int J Cancer, 2006, 119(2): 243-250.
|
| [12] |
Brown D, Waneck GL. Glycosyl-phosphatidylinositol-anchored membrane proteins[J]. J Am Soc Nephrol, 1992, 3(4): 895-906.
|
| [13] |
O′Shannessy DJ, Somers EB, Palmer L M, et al. Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4[J]. J Ovarian Res, 2012, 6(1): 29.
|
| [14] |
Basal E, Eghbali-Fatourechi GZ, Kalli KR, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients[J]. PLoS One, 2009, 4(7): e6292.
|
| [15] |
Kurosaki A, Hasegawa K, Kato T, et al. Serum folate receptor alpha as a biomarker for ovarian cancer: implications for diagnosis, prognosis and predicting its local tumor expression[J]. Int J Cancer, 2015, 138(8): 1994-2002.
|
| [16] |
Jacobs I, Bast RC Jr. The CA125 tumour-associated antigen: a review of the literature[J]. Hum Reprod, 1989, 4(1): 1-12.
|
| [17] |
Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications[J]. Cancer Metastasis Rev, 2015, 34(1): 41-52.
|
| [18] |
Wang L, Wallace A, Raghavan S, et al. 6-substituted pyrrolo[2, 3-d]pyrimidine thienoyl regioisomers as targeted antifolates for folate receptor and the proton-coupled folate transporter in human tumors[J]. J Med Chem, 2015, 58(17): 6938-6959.
|
| [19] |
Amato RJ, Shetty A, Lu Y, et al. A phase Ⅰ study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma[J]. J Immunother, 2013, 36(4): 268-275.
|
| [20] |
Li S, Tong J, Rahman MM, et al. Oncolytic virotherapy for ovarian cancer[J]. Oncolyt Virother, 2012, 1(1): 1-21.
|
| [21] |
Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents[J]. Cancer Metastasis Rev, 2008, 27(4): 655-664.
|
| [22] |
Despierre E, Lambrechts S, Leunen K, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy[J]. Gynecol Oncol, 2013, 130(1): 192-199.
|